Projects per year
Personal profile
Area of Expertise
The focus of my research has two broad aims.
The first aim is to screen compounds that will attenuate the subjective and reinforcing effects of abused drugs as part of a NIDA-funded contract searching for effective treatment drugs for addiction to cocaine, methamphetamine, nicotine, and marijuana.
The second aim is to evaluate the potential abuse liability of novel designer drugs that are increasingly available as "legal" alternatives to controlled substances. We use drug discrimination procedures which assess the subjective effects of common drugs of abuse such as cocaine, methamphetamine, nicotine, and marijuana, with designer drugs like MDMA (Ecstasy), with opioids like morphine, or with hallucinogens like LSD. We also test the reinforcing/rewarding effects of drugs using the conditioned place preference and self-administration assays.
The first aim is to screen compounds that will attenuate the subjective and reinforcing effects of abused drugs as part of a NIDA-funded contract searching for effective treatment drugs for addiction to cocaine, methamphetamine, nicotine, and marijuana.
The second aim is to evaluate the potential abuse liability of novel designer drugs that are increasingly available as "legal" alternatives to controlled substances. We use drug discrimination procedures which assess the subjective effects of common drugs of abuse such as cocaine, methamphetamine, nicotine, and marijuana, with designer drugs like MDMA (Ecstasy), with opioids like morphine, or with hallucinogens like LSD. We also test the reinforcing/rewarding effects of drugs using the conditioned place preference and self-administration assays.
Education/Academic qualification
BA in Behavioral Science, The University of Chicago
MA in Behavior Science, University of Houston
PhD in Psychology , Utah State University
Fingerprint
Dive into the research topics where Michael Gatch is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Using rodent behavioral models to identify substance abuse pharmacotherapies
Forster, M. (PI), Gatch, M. (CoI), Shetty, R. (CoI) & Sumien, N. (CoI)
NIDA: National Institute on Drug Abuse
4/01/23 → 3/01/28
Project: Research
-
-
-
-
-
Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats
Gatch, M. B., Rutledge, M. A., Carbonaro, T. & Forster, M. J., Jul 2009, In: Psychopharmacology. 204, 4, p. 715-724 10 p.Research output: Contribution to journal › Article › peer-review
-
Locomotor, discriminative stimulus, and place conditioning effects of MDAI in rodents
Gatch, M. B., Dolan, S. B. & Forster, M. J., 1 Sep 2016, In: Behavioural pharmacology. 27, 6, p. 497-505 9 p.Research output: Contribution to journal › Article › peer-review
-
Effects of NMDA antagonists on ethanol-withdrawal induced 'anxiety' in the elevated plus maze
Gatch, M. B., Wallis, C. J. & Lal, H., Nov 1999, In: Alcohol. 19, 3, p. 207-211 5 p.Research output: Contribution to journal › Article › peer-review
-
Impure but not inactive: Behavioral pharmacology of dibenzylpiperazine, a common by-product of benzylpiperazine synthesis
Dolan, S. B., Shetty, R. A., Forster, M. J. & Gatch, M. B., 1 Jul 2018, In: Journal of Psychopharmacology. 32, 7, p. 802-810 9 p.Research output: Contribution to journal › Article › peer-review
-
Effects of monoamine oxidase inhibitors on cocaine discrimination in rats
Gatch, M. B., Taylor, C. M., Flores, E., Selvig, M. & Forster, M. J., Mar 2006, In: Behavioural pharmacology. 17, 2, p. 151-159 9 p.Research output: Contribution to journal › Article › peer-review